ESC Premium Access

Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study

Congress Presentation

About the speaker

Associate Professor Marco Proietti

University of Milan, Milan (Italy)
11 presentations
0 follower

7 more presentations in this session

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with antiphospholipid syndrome: a nationwide cohort study

Speaker: Assistant Professor P. Yang (Seongnam, KR)

Thumbnail

Reduced stroke risk without increased bleeding risk in patients with atrial fibrillation and complicated liver cirrhosis treated with oral anticoagulation

Speaker: Doctor K. Steensig (Aalborg, DK)

Thumbnail

Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

Is there a role for half-dose anticoagulation in atrial fibrillation? Randomized comparison of 2 doses of edoxaban in 14,014 patients in ENGAGE AF-TIMI 48

Speaker: Professor J. Steffel (Zurich, CH)

Thumbnail

Recommended and non-recommended edoxaban dosing in patients with atrial fibrillation (AF): one-year clinical events from the Global ETNA-AF non-interventional study (NIS)

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

Access the full session

Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation in ‘Special’ Situations

Speakers: Associate Professor M. Proietti, Assistant Professor P. Yang, Doctor K. Steensig, Doctor T. Chao, Professor J. Steffel...
Thumbnail

About the event

Image

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb